Tag: cancer

1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. ...

Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...

Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...

1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...

1. This prospective study found that the Systematic Inflammatory Response Index (SIRI) and Systemic Immune-Inflammation Index (SII), as well as ...

1. Despite lower prevalence of traditional cardiovascular risk factors, cancer patients were observed to have similar cardiovascular disease (CVD) events ...

Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...

1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...

1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...

1. In patients with mantle-cell lymphoma who responded to induction therapy and autologous stem cell transplantation, rituximab maintenance therapy prolonged ...